Key Oncologics to Market Eligard™ in South Africa
By Business Review Editor
Pharma Deals Review: Vol 2002 Issue 28 (Table of Contents)
Published: 2 Sep-2002
DOI: 10.3833/pdr.v2002.i28.1015 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Atrix Laboratories signed an agreement providing Key Oncologics with the South African marketing rights for its Eligard™ (injectable leuprolide acetate suspension) prostate cancer products...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018